{"id":"incmga00012","safety":{"commonSideEffects":[{"rate":null,"effect":"Immune-related colitis"},{"rate":null,"effect":"Immune-related hepatitis"},{"rate":null,"effect":"Immune-related pneumonitis"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Rash"}]},"_chembl":{"chemblId":"CHEMBL4298037","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"CTLA-4 is an inhibitory receptor on T cells that suppresses immune responses. By blocking CTLA-4, this antibody removes a key brake on T-cell activation, allowing enhanced proliferation and effector function of tumor-infiltrating lymphocytes. This mechanism is designed to potentiate anti-tumor immune responses in cancer patients.","oneSentence":"INCMGA00012 is an anti-CTLA-4 monoclonal antibody that blocks immune checkpoint inhibition to enhance T-cell activation and anti-tumor immunity.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:35:58.756Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic melanoma"},{"name":"Other solid tumors (in combination with checkpoint inhibitors)"}]},"trialDetails":[{"nctId":"NCT03328026","phase":"PHASE1, PHASE2","title":"Combination Study of SV-BR-1-GM With Retifanlimab","status":"COMPLETED","sponsor":"BriaCell Therapeutics Corporation","startDate":"2018-03-16","conditions":"Breast Cancer, Breast Neoplasm, Metastatic Breast Cancer","enrollment":36},{"nctId":"NCT04387084","phase":"PHASE1","title":"Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Southern California","startDate":"2020-08-12","conditions":"Advanced Malignant Skin Neoplasm, Metastatic Malignant Skin Neoplasm","enrollment":10},{"nctId":"NCT07468136","phase":"PHASE1, PHASE2","title":"Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas","status":"NOT_YET_RECRUITING","sponsor":"Mayo Clinic","startDate":"2026-04-24","conditions":"Anaplastic Oligodendroglioma, Astrocytoma, IDH-Mutant, Grade 3, Astrocytoma, IDH-Mutant, Grade 4","enrollment":33},{"nctId":"NCT05743595","phase":"PHASE1","title":"Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2023-10-27","conditions":"Unmethylated Glioblastoma","enrollment":27},{"nctId":"NCT04205812","phase":"PHASE3","title":"Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Incyte Corporation","startDate":"2020-09-11","conditions":"Metastatic Squamous Non-Small Cell Lung Cancer, Metastatic Nonsquamous Non-Small Cell Lung Cancer","enrollment":583},{"nctId":"NCT04577014","phase":"PHASE1, PHASE2","title":"Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2020-09-29","conditions":"Soft Tissue Sarcoma, Sarcoma,Soft Tissue, Sarcoma","enrollment":98},{"nctId":"NCT06056895","phase":"PHASE2","title":"Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Washington","startDate":"2023-11-08","conditions":"Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Merkel Cell Carcinoma AJCC v8, Merkel Cell Carcinoma","enrollment":12},{"nctId":"NCT05083754","phase":"PHASE1","title":"Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2022-08-31","conditions":"Glioblastoma Multiforme","enrollment":50},{"nctId":"NCT06910137","phase":"","title":"An Early Access Program Guideline to Provide Access to Retifanlimab (INCMGA00012) Together With Carboplatin and Paclitaxel for Squamous Carcinoma of the Anal Canal (SCAC)","status":"AVAILABLE","sponsor":"Incyte Corporation","startDate":"","conditions":"Squamous Cell Carcinoma of the Anal Canal","enrollment":""},{"nctId":"NCT06320405","phase":"PHASE1, PHASE2","title":"Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2024-05-21","conditions":"Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm","enrollment":38},{"nctId":"NCT05455697","phase":"PHASE1, PHASE2","title":"Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma","status":"RECRUITING","sponsor":"University of Washington","startDate":"2023-01-26","conditions":"Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma","enrollment":35},{"nctId":"NCT04463771","phase":"PHASE2","title":"Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Incyte Corporation","startDate":"2021-01-26","conditions":"Endometrial Cancer","enrollment":206},{"nctId":"NCT03532295","phase":"PHASE2","title":"Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2020-04-20","conditions":"Glioma, Glioblastoma","enrollment":51},{"nctId":"NCT04472429","phase":"PHASE3","title":"Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2021-01-12","conditions":"Squamous Cell Carcinoma of the Anal Canal","enrollment":308},{"nctId":"NCT04438824","phase":"PHASE2","title":"Palbociclib and INCMGA00012 in People With Advanced Liposarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2020-06-17","conditions":"Well-differentiated/Dedifferentiated Liposarcoma","enrollment":42},{"nctId":"NCT03522142","phase":"PHASE1","title":"A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies","status":"TERMINATED","sponsor":"Incyte Corporation","startDate":"2018-08-27","conditions":"Advanced Solid Tumors","enrollment":83},{"nctId":"NCT04370704","phase":"PHASE1, PHASE2","title":"Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2020-07-27","conditions":"Melanoma","enrollment":61},{"nctId":"NCT03597295","phase":"PHASE2","title":"A Study of INCMGA00012 in Squamous Carcinoma of the Anal Canal Following Platinum-Based Chemotherapy (POD1UM-202)","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2018-10-08","conditions":"Squamous Cell Carcinoma of Anal Canal","enrollment":94},{"nctId":"NCT04225039","phase":"PHASE2","title":"Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2020-06-23","conditions":"Glioblastoma","enrollment":39},{"nctId":"NCT04968106","phase":"PHASE2","title":"Neoadjuvant Chemotherapy and Retifanlimab in Patients With Selected Sarcomas (TORNADO)","status":"RECRUITING","sponsor":"Institut Bergonié","startDate":"2022-12-07","conditions":"Resectable Sarcoma","enrollment":66},{"nctId":"NCT02475213","phase":"PHASE1","title":"Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer","status":"COMPLETED","sponsor":"MacroGenics","startDate":"2015-07","conditions":"Melanoma, Head and Neck Cancer, Non Small Cell Lung Cancer","enrollment":146},{"nctId":"NCT03599713","phase":"PHASE2","title":"A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201)","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2019-02-25","conditions":"Metastatic Merkel Cell Carcinoma","enrollment":107},{"nctId":"NCT03059823","phase":"PHASE1","title":"A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2016-11-15","conditions":"Locally Advanced Solid Tumors, Metastatic Solid Tumors","enrollment":325},{"nctId":"NCT04116073","phase":"PHASE2","title":"INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic or Ampullary Cancer","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2020-04-09","conditions":"Pancreatic Cancer Non-resectable, Pancreatic Cancer Metastatic","enrollment":25},{"nctId":"NCT05239182","phase":"PHASE2","title":"9-ING-41 Plus Retifanlimab and Gemcitabine/Nab-Paclitaxel in Patients With Advanced Pancreatic Adenocarcinoma","status":"TERMINATED","sponsor":"Anwaar Saeed","startDate":"2022-01-26","conditions":"Pancreatic Adenocarcinoma","enrollment":7},{"nctId":"NCT04580485","phase":"PHASE1","title":"INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2021-02-03","conditions":"Ovarian Cancer, Bladder Cancer, Non Small Cell Lung Cancer","enrollment":54},{"nctId":"NCT04470024","phase":"PHASE1","title":"Phase Ib Trial of Multivalent Autophagosome Vaccine With or Without GITR Agonist, With Anti-PD-1 Immunotherapy in HNSCC","status":"RECRUITING","sponsor":"Providence Health & Services","startDate":"2021-08-05","conditions":"Cancer of the Head and Neck","enrollment":56},{"nctId":"NCT04082364","phase":"PHASE2, PHASE3","title":"Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer","status":"COMPLETED","sponsor":"MacroGenics","startDate":"2019-09-30","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer, HER2-positive Gastric Cancer","enrollment":82},{"nctId":"NCT05440942","phase":"PHASE1","title":"Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma","status":"COMPLETED","sponsor":"Peter Hosein, MD","startDate":"2023-01-19","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":28},{"nctId":"NCT04231981","phase":"PHASE2","title":"Efficacy of INCMGA00012 in Penile Squamous Cell Carcinoma (ORPHEUS)","status":"COMPLETED","sponsor":"MedSIR","startDate":"2020-04-28","conditions":"Penile Cancer","enrollment":18},{"nctId":"NCT04494009","phase":"PHASE2","title":"PD-1 Inhibitor INCMGA00012 as Consolidation Therapy After Definitive Concurrent Chemoradiotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Asan Medical Center","startDate":"2020-09-07","conditions":"Esophageal Cancer","enrollment":110},{"nctId":"NCT04445844","phase":"PHASE2","title":"INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mridula George, MD","startDate":"2020-07-13","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma","enrollment":25},{"nctId":"NCT06160206","phase":"PHASE2","title":"Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma","status":"RECRUITING","sponsor":"Academic and Community Cancer Research United","startDate":"2024-10-02","conditions":"Recurrent Glioblastoma, Recurrent WHO Grade 4 Glioma","enrollment":134},{"nctId":"NCT04949191","phase":"PHASE2","title":"The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies.","status":"TERMINATED","sponsor":"Incyte Corporation","startDate":"2021-07-08","conditions":"Advanced Malignancies","enrollment":10},{"nctId":"NCT05177133","phase":"PHASE2","title":"Anti-PD-1 and CapOx for the First-line Treatment of dMMR Esophagogastric Cancer (AuspiCiOus)","status":"RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2021-11-05","conditions":"Gastric Adenocarcinoma, Esophageal Adenocarcinoma","enrollment":25},{"nctId":"NCT04634825","phase":"PHASE2","title":"Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer","status":"TERMINATED","sponsor":"MacroGenics","startDate":"2021-03-17","conditions":"Head and Neck Cancer, Head and Neck Neoplasms, Head and Neck Squamous Cell Carcinoma","enrollment":62},{"nctId":"NCT03679767","phase":"PHASE2","title":"A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2019-01-09","conditions":"Metastatic Non-small Cell Lung Cancer, Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer","enrollment":121},{"nctId":"NCT04799431","phase":"PHASE1","title":"Neoantigen-Targeted Vaccine Combined With Anti-PD-1 Antibody for Patients With Stage IV MMR-p Colon and Pancreatic Ductal Cancer","status":"WITHDRAWN","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2023-05-03","conditions":"Pancreatic Cancer Metastatic, Colorectal Cancer Metastatic","enrollment":""},{"nctId":"NCT03589651","phase":"PHASE1","title":"INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2018-08-17","conditions":"Unresectable or Metastatic Solid Tumors","enrollment":83},{"nctId":"NCT02393248","phase":"PHASE1, PHASE2","title":"Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)","status":"TERMINATED","sponsor":"Incyte Corporation","startDate":"2015-02-27","conditions":"Lung Cancer, Solid Tumor, Gastric Cancer","enrollment":201},{"nctId":"NCT03406949","phase":"PHASE1","title":"MGD009/MGA012 Combination in Relapsed/Refractory Cancer","status":"COMPLETED","sponsor":"MacroGenics","startDate":"2018-02-27","conditions":"Advanced Solid Tumors","enrollment":25},{"nctId":"NCT03910530","phase":"PHASE1","title":"A Study of INCMGA00012, INCB001158, and the Combination in Japanese Participants With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Incyte Biosciences Japan GK","startDate":"2019-07-22","conditions":"Advanced Solid Tumors, Metastatic Solid Tumors","enrollment":18},{"nctId":"NCT04129320","phase":"PHASE2, PHASE3","title":"Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and Neck","status":"WITHDRAWN","sponsor":"MacroGenics","startDate":"2019-10","conditions":"Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck","enrollment":""},{"nctId":"NCT03531632","phase":"PHASE1, PHASE2","title":"MGD007 Combined With MGA012 in Relapsed/Refractory Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"MacroGenics","startDate":"2018-06-04","conditions":"Colorectal Cancer Metastatic","enrollment":38},{"nctId":"NCT04776876","phase":"PHASE2","title":"Retifanlimab (INCMGA00012) and Telotristat Ethyl for the Treatment of Advanced Neuroendocrine Tumors and Carcinoid Syndrome","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-03-01","conditions":"Advanced Neuroendocrine Neoplasm, Carcinoid Syndrome","enrollment":""},{"nctId":"NCT04203511","phase":"PHASE3","title":"INCMGA00012 in Combination With Chemoradiation in Participants With Stage III Non-Small Cell Lung Cancer (POD1UM-301)","status":"WITHDRAWN","sponsor":"Incyte Corporation","startDate":"2020-07-31","conditions":"Non-small Cell Lung Cancer","enrollment":""},{"nctId":"NCT03920839","phase":"PHASE1","title":"INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105)","status":"WITHDRAWN","sponsor":"Incyte Corporation","startDate":"2019-07-15","conditions":"Advanced and/or Metastatic Solid Tumors, Stage IIIB Not Amenable to Curative Therapy to Stage IV Non-small Cell Lung Cancer, Advanced/Metastatic Unresectable Malignant Pleural Mesothelioma","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Retifanlimab","PD-1 inhibitor","PD1","retifanlimab"],"phase":"phase_2","status":"active","brandName":"INCMGA00012","genericName":"INCMGA00012","companyName":"Providence Health & Services","companyId":"providence-health-services","modality":"Small molecule","firstApprovalDate":"","aiSummary":"INCMGA00012 is an anti-CTLA-4 monoclonal antibody that blocks immune checkpoint inhibition to enhance T-cell activation and anti-tumor immunity. Used for Advanced or metastatic melanoma, Other solid tumors (in combination with checkpoint inhibitors).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":8,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}